Telmisartan alleviates collagen type III glomerulopathy: A case report with literature review

Abstract

Collagen type III is commonly detected in the renal interstitium and vasculature; however, it is absent in healthy glomeruli. Deposition of collagen type III in the glomerular mesangium and capillary basement membranes may arise in two rare diseases, namely collagen type III glomerulopathy (CG) and nail patella syndrome. CG is a rare glomerular disease with no specific treatment, although supportive measures for control of hypertension and edema may help to relieve symptoms. With progression to end-stage renal disease, patients with CG may come to require dialysis and/or renal transplantation. The present study reported on a 59-year-old male who was diagnosed with CG nephrotic syndrome by immunohistochemical and electron microscopic examination of biopsy material. To the best of our knowledge, this is the first case reported in northeastern China. The angiotensin II blocker telmisartan was successfully used to alleviate renal symptoms and a literature review was performed. The present case supports the use of telmisartan as a first choice of treatment for CG.

Anti-Apoptosis of Podocytes and Pro-Apoptosis of Mesangial Cells for Telmisartan in Alleviating Diabetic Kidney Injury

“…Blockade of the renin–angiotensin system ameliorates the expression of ANGPTL2 and integrin which maintain the glomerular barrier ( Tawfik et al, 2021 ). The reason telmisartan was chosen is that it is described more efficient than other ARB drugs in mitigating proteinuria ( Naruse et al, 2019 ; Guo et al, 2020 ). Moreover, telmisartan is able to decrease cisplatin-induced nephrotoxicity such as podocytes apoptosis and autophagy-associated protein expression levels ( Malik et al, 2015 ).…”